Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Apr;35(4):1778-1785.
doi: 10.1007/s00464-020-07572-x. Epub 2020 Apr 23.

Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis

L Rodríguez-Ortiz #  1 , A Arjona-Sánchez #  2 , M Ibañez-Rubio  1 , J Sánchez-Hidalgo  1 , A Casado-Adam  1 , S Rufián-Peña  1 , J Briceño-Delgado  1
Affiliations
Comparative Study

Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis

L Rodríguez-Ortiz et al. Surg Endosc. 2021 Apr.

Abstract

Background: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure that has had encouraging results for peritoneal metastases (PM) from diverse tumour origins, but it is not exempt from high morbidity. Recently, the important role of laparoscopy in oncologic surgeries and its benefits have been evaluated for CRS + HIPEC in selected patients, which has yielded promising results. The aim of our study is to analyse the use of laparoscopy for CRS + HIPEC in patients with limited peritoneal disease.

Methods: We have conducted a retrospective study from a prospective database in our tertiary referral hospital within the period of January 2009 to July 2019, which includes 825 patients who had PM from varying tumour origins. We have compared the patients treated with the laparoscopic approach (L-CRS-HIPEC) to a matched population who have undergone the open approach (O-CRS-HIPEC) and fulfil the same selection criteria. We have analysed the postoperative outcomes and survival results.

Results: We have confirmed the homogeneity between the sample of the O-CRS + HIPEC (n = 42) and the L-CRS + HIPEC (n = 18) regarding preoperative and intraoperative features. The L-CRS + HIPEC group had shorter hospital stays, (median of 4 [2-10] days versus 9 [2-19] days) and reduced wait time to return to chemotherapy (median of 4 [3-7] weeks and a median of 8 [4-36] weeks) than the O-CRS + HIPEC group. No differences were found regarding the need for perioperative blood transfusion, surgery time or postoperative morbi-mortality. No early locoregional relapse occurred in the L-CRS + HIPEC group and short term disease-free survival did not differ between groups.

Conclusions: Laparoscopy for CRS + HIPEC is feasible and safe in highly selected patients, with no significant differences concerning postoperative morbi-mortality or early oncological results. We have found that patients who have undergone laparoscopic operations have shorter hospital stays and that they return to adjuvant chemotherapy sooner. Further investigation is required to confirm the benefits of minimally invasive procedures for the management of PM.

Keywords: Cytoreductive surgery; HIPEC; Laparoscopy; Minimally invasive surgery.

PubMed Disclaimer

References

    1. Arjona-Sanchez AR-PS, Sanchez-Hidalgo JM, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J (2018) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (HIPEC) by minimally invasive approach, an initial experience. World J Surg 42(10):3120–3124. https://doi.org/10.1007/s00268-018-4634-6 - DOI - PubMed
    1. Mercier F, Jeremie G, Alyami M et al (2019) Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. Surg Endosc. https://doi.org/10.1007/s00464-019-07280-1 - DOI - PubMed
    1. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240. https://doi.org/10.1056/NEJMoa1708618 - DOI - PubMed
    1. Sánchez-Hidalgo JM, Rodríguez-Ortiz L, Arjona-Sánchez Á, Rufián-Peña S, Casado-Adam Á, Cosano-Álvarez A, Briceño-Delgado J (2019) Colorectal peritoneal metastases: optimal management review. World J Gastroenterol 25(27):3484–3502. https://doi.org/10.3748/wjg.v25.i27.3484 - DOI - PubMed - PMC
    1. Tempfer CB, Kern P, Dogan A, Hilal Z, Rezniczek GA (2019) Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for endometrial cancer-derived peritoneal metastases: a systematic review. Clin Exp Metastasis 36(4):321–329. https://doi.org/10.1007/s10585-019-09970-5 - DOI - PubMed

Publication types

LinkOut - more resources